# 510(k) Summary

# BD ProbeTec™ Herpes Simplex Viruses (HSV1 & 2) Qr Amplified DNA Assays

# Applicant

BD Diagnostic Systems 7 Loveton Circle Sparks, MD 21152

# Establishment Registration No. 1119779

MAR 1 8 2011

# Contact Person

Thalia Charles tel. 410-316-4145 fax. 410-316-4499 Thalia E Charles@bd.com

# Summary Date

·March 14, 2011

Proprietary Name

BD ProbeTec™M Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays

# Generic Name

DNA probe, nucleic acid amplification, Herpes Simplex virus

Classification Classification Name Regulation Number Product Code

Class ⅡI   
Herpes simplex virus serological assays   
21 CFR 866.3305   
0Q0

Predicate Device

ELVIS HSV ID and $\mathbf { D } ^ { 3 }$ Typing Test System

# Device Description

The BD ProbeTec Herpes Simplex Viruses (HSV 1 & 2) $\mathbf { Q } ^ { \mathbf { x } }$ Amplified DNA Assays (HSV $\mathbf { Q } ^ { \mathbf { x } }$ Assays) are based on the simultaneous amplification and detection of target DNA using amplification primers and fluorescently-labeled detector probes. The reagents for SDA are dried in two separate disposable microwells for each HSV Q\* Assay: the Priming Microwell contains the amplification primers, fluorescently-labeled detector probe, nucleotides and other reagents necessary for amplification, while the Amplification Microwell contains the two enzymes (a DNA polymerase and a restriction endonuclease) that are required for SDA. The BD Viper1 TM System pipettes a portion of the purified DNA solution from each Extraction Tube into a Priming Microwell to rehydrate the contents. After a brief incubation, the reaction mixture is transferred to a corresponding, pre-warmed Amplification Microwell which is then sealed to prevent contamination and incubated in one of the two thermally-controlled fluorescent readers. The presence or absence of Herpes Simplex virus type 1 (HSV1) or Herpes Simplex virus type 2 (HSV2) DNA is determined by calculating the peak fluorescence (Maximum Relative

# 510(k) Summary

# BD ProbeTecT™ Herpes Simplex Viruses (HSV1 & 2) Q Amplified DNA Assays

Fluorescent Units (MaxRFU)) over the course of the amplification process and by comparing this measurement to a predetermined threshold value.

In addition to the fluorescent probe used to detect amplified HSV1 or HSV2 target DNA, a second labeled oligonucleotide is incorporated in each reaction. The Extraction Control (EC) oligonucleotide is labeled with a different dye than that used for detection of the HSV1 or HSV2 specific target and is used to confirm the validity of the extraction process. The EC is dried in the Extraction Tubes and is rehydrated upon addition of the specimen and extraction reagents. At the end of the extraction process, the EC fluorescence is monitored by the BD Viper System and an automated algorithm is applied to both the EC and target-specific signals to report results as positive, negative, or EC failure.

# Intended Use

The BD ProbeTecTM Herpes Simplex Viruses (HSV 1 & 2) $\mathbf { Q } ^ { x }$ Amplified DNA Assays, when tested with the BD Viper™M System in Extracted Mode, use Strand Displacement Amplification technology for the direct, qualitative detection and differentiation of Herpes Simplex virus type 1 (HSV1) and Herpes Simplex virus type 2 (HSV2) DNA in clinician-collected external anogenital lesion specimens. The assays are indicated for use with symptomatic individuals to aid in the diagnosis of anogenital HSV1 and HSV2 infections.

Warning: The BD ProbeTecTM Herpes Simplex Viruses (HSV 1 & 2) ${ { \bf { Q } } ^ { \bf { \arctan } } }$ Amplified DNA Assays (HSV $\mathbf { Q } ^ { \pmb { x } }$ Assays) are not FDA cleared for use with cerebrospinal fluid (CSF). The assays are not intended to be used for prenatal screening or for individuals under the age of 17 years.

# Summary and Principles of Operation

When used with the BD Viper System, the BD ProbeTec HSV ${ \bf { \cal Q } } ^ { \tt x }$ Amplified DNA Assays involve automated extraction of DNA from clinical specimens through the chemical lysis of cells, followed by binding of DNA to para-magnetic particles, washing of the bound nucleic acid, and elution in an amplification-compatible buffer. When present, HSV1 or HSV2 DNA is then detected by Strand Displacement Amplification (SDA) of either specific target sequence in the presence of a fluorescently-labeled detector probe.

# Analytical Performance Characteristics

# Limit of Detection (Analytical Sensitivity)

The Limits of Detection (LODs) for the HSV1 Q\* Assay with HSV1 ATCC strain VR-539 in model matrix specimens when extracted on the BD Viper System were determined to be 23 viral particles/mL (vp/mL) in the Q" Swab Diluent medium, and 85 vp/mL in the Universal Viral Transport medium (UVT). These values correspond to 7 TCID50/mL and 25 TCID50/mL,

# 510(k) Summary

# BD ProbeTecT Herpes Simplex Viruses (HSV1 & 2) $\mathbf { Q } ^ { \star }$ Amplified DNA Assays

respectively. The Limits of Detection (LODs) for the HSV2 Q\* Assay with HSV2 ATCC strain VR-734 in model matrix specimens when extracted on the BD Viper System were determined to be ${ \bf 8 4 v p / m L }$ (35 $\mathrm { \Delta T C I D _ { 5 0 } / m L ) }$ in the $\mathsf { Q } ^ { x }$ Swab Diluent medium and $6 3 5 ~ \mathrm { v p / m L }$ $( 2 6 2 \mathrm { T C I D } _ { 5 0 } / \mathrm { m L } )$ EMPY in the UVT medium. Evaluation of the HSV 1 $\mathsf { Q } ^ { x }$ Assay on the BD Viper System in extracted mode with three additional HSV1 strains gave LoD values between 6 and 14 vp/mL in clean Qx Swab Diluent and between 110 and $1 8 5 ~ \mathrm { v p / m L }$ in clean UVT. Evaluation of the HSV2 $\mathbf { Q } ^ { \boldsymbol { \mathfrak { x } } }$ Assay on the BD Viper System in extracted mode with one additional HSV2 strain gave an LOD of 34 $\mathbf { v } _ { \mathrm { P } } / \mathbf { m L }$ in clean $\mathsf { Q } ^ { \boldsymbol { \mathsf { x } } }$ Swab Diluent and $3 8 0 \mathrm { v p / m L }$ in clean UVT.

# Analytical Specificity

The DNA from 57 organisms was extracted on the BD Viper System and tested with the BD ProbeTec HSV $\mathbf { Q } ^ { \star }$ Amplified DNA Assays. All potential cross-reactive species were tested at approximately $\overline { { 1 \times 1 0 ^ { 8 } } }$ Colony Forming Units/mL for bacteria and yeast or $\boldsymbol { 1 } \mathbf { x } \boldsymbol { 1 } 0 ^ { 6 }$ Plaque Forming Units/mL or greater for viruses, except where noted. Results are summarized in Table 1.

Table 1: Potential Cross-Reactants   

<table><tr><td rowspan=1 colspan=1>Actinomyces israelii</td><td rowspan=1 colspan=1>Human papillomavirus 16&#x27;</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Human papillomavirus 181</td></tr><tr><td rowspan=1 colspan=1>Alcaligenes faecalis</td><td rowspan=1 colspan=1>Kingella kingae</td></tr><tr><td rowspan=1 colspan=1>Candida albicuns</td><td rowspan=1 colspan=1>Klebsiella pneumoniae</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis serovar H</td><td rowspan=1 colspan=1>Lactobacillus acidophilus</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis serovar LGV-2</td><td rowspan=1 colspan=1>Listeria monocylogenes</td></tr><tr><td rowspan=1 colspan=1>Clostridium perfringens</td><td rowspan=1 colspan=1>Mobiluncus mulieris</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium genitalium</td><td rowspan=1 colspan=1>Moraella lacunata</td></tr><tr><td rowspan=1 colspan=1>Cryptococcus neoformans</td><td rowspan=1 colspan=1>Mycobacterium tuberculosis</td></tr><tr><td rowspan=1 colspan=1>HHV-5 Cytomegalovinus (CMV)</td><td rowspan=1 colspan=1>Mycoplasma genitalium</td></tr><tr><td rowspan=1 colspan=1>Enterobacter cloacae</td><td rowspan=1 colspan=1>Neisseria gonorrhoeae</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecalis</td><td rowspan=1 colspan=1>Neisseria meningitidis</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecium</td><td rowspan=1 colspan=1>Propionibacterium acnes</td></tr><tr><td rowspan=1 colspan=1>Enterovinus (Echovinus 11)</td><td rowspan=1 colspan=1>Proteus vulgaris</td></tr><tr><td rowspan=1 colspan=1>HHV.4 Epstein Barr virus²</td><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli (strain K1)</td><td rowspan=1 colspan=1>Staphylococcus aureus</td></tr><tr><td rowspan=1 colspan=1>Gardnerella vaginalis</td><td rowspan=1 colspan=1>Staphylococcus epidermidis</td></tr><tr><td rowspan=1 colspan=1>Gemella haemolysans</td><td rowspan=1 colspan=1>Staphylococcus saprophyticus</td></tr><tr><td rowspan=1 colspan=1>Haemophilus ducreyi</td><td rowspan=1 colspan=1>Streptococcus agalactiae</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenzae</td><td rowspan=1 colspan=1>Streptococcus mitis</td></tr><tr><td rowspan=1 colspan=1>Hepatitis B Vinus&#x27;</td><td rowspan=1 colspan=1>Streptococcus pneumoniae</td></tr><tr><td rowspan=1 colspan=1>HHV-6 (Roseolovirus)</td><td rowspan=1 colspan=1>Streptococcus pyogenes</td></tr><tr><td rowspan=1 colspan=1>HHV-6B (Roseolovinus)</td><td rowspan=1 colspan=1>Treponema pallidum</td></tr><tr><td rowspan=1 colspan=1>HHV-7 (Roseolovirus)</td><td rowspan=1 colspan=1>Trichomonas vaginalis</td></tr></table>

# 510(k) Summary

# BD ProbeTecT™ Herpes Simplex Viruses (HSV1 & 2) Qx Amplified DNA Assays

<table><tr><td rowspan=1 colspan=1>HHV-8 (Rhadinovirus)</td><td rowspan=1 colspan=1>Varicella Zoster Virnus (HHV-3)</td></tr><tr><td rowspan=1 colspan=1>Human Immunodeficiency Virus 1 (HIV-1)2</td><td rowspan=1 colspan=1>Veillonella parvula</td></tr><tr><td rowspan=1 colspan=1>Human Immunodeficiency Virus 2 (HIV-2)²2</td><td rowspan=1 colspan=1>Herpes Virus Type 1 (HSV1)^²*</td></tr><tr><td rowspan=1 colspan=1>Human papillomavirus 6</td><td rowspan=1 colspan=1>Herpes Virus Type 2 (HSV2)2**</td></tr><tr><td rowspan=1 colspan=1>Human papillomavirus 11</td><td rowspan=1 colspan=1></td></tr></table>

1 Genomic DNA tested at $1 \times 1 0 ^ { 6 }$ DNA copies/mL 2 Viruses tested at $\mathrm { 1 } \mathbf { x } \mathrm { 1 0 ^ { 8 } }$ viral particles/ml \* Tested as a cross-reactant in the HSV2 $\mathbf { Q } ^ { \star }$ Assay only \*\* Tested as a cross-reactant in the HSVI $\mathsf { Q } ^ { \mathsf { x } }$ Assay only

# Interfering Substances

Potentially interfering substances which may be encountered in external anogenital lesion specimens were tested in the absence and presence of HSV1 and HSV2 targets (for HSV1 target, $6 9 \mathrm { v p / m L }$ in $\mathbf { Q x }$ Swab Diluent and $2 5 5 \mathrm { v p / m L }$ in UVT; for HSV2 target, $2 5 2 ~ \mathrm { v p / m L }$ in $\mathbf { Q x }$ Swab Diluent and $1 9 0 5 \ \mathrm { v p / m L }$ in UVT; these levels are 3 times each LOD) and tested with the BD ProbeTec HSV $\mathbf { Q } ^ { \mathbf { x } }$ Amplified DNA Assays on the BD Viper System. Results are summarized in Table 2.

Table 2: Potentially Interfering Substances   

<table><tr><td>Interpretation</td><td>Q&quot; Swab Diluent</td><td>UVT</td></tr><tr><td></td><td>Blood (2.5% v/v) Seminal fluid (2.5% v/v) Mucus (2.5% v/v) Feces (2.5%)</td><td>Blood (3.3% v/v) Seminal fluid (3.3% v/v) Mucus (3.3% v/v) Feces (3.3%)</td></tr><tr><td>No interference observed</td><td>Urine (2.5% v/v) Cornstarch (2.5%) Over the counter vaginal products and contraceptives (2.5% v/v) Over the counter cold sore products</td><td>Urine (3.3% v/v) Cornstarch (3.3%) Over the counter vaginal products and contraceptives (3.3% v/v) Over the counter cold sore products</td></tr><tr><td>at levels listed</td><td>(2.5% v/v) Hemorrhoidal cream (2.5% v/v) Prescription vaginal and anti-viral treatments (2.5% v/v) Leukocytes (1x106 cells/mL)</td><td>(3.3% v/v) Hemorrhoidal cream (3.3% v/v) Prescription vaginal and anti-viral treatments (3.3% v/v) Leukocytes (1x106 cells/mL)</td></tr><tr><td></td><td>1x106 viral particles/mL HSVI (when tested in the HSV2 Q&quot; assay)</td><td>1x10° viral particles/mL HSV1 (when tested in the HSV2 Q&quot; assay)</td></tr><tr><td></td><td>1x106 viral particles/mL HSV2</td><td>1x10° viral particles/mL HSV2</td></tr><tr><td>May cause extraction control (EC) failures</td><td>(when tested in the HSVI Q&quot; assay) Not applicable</td><td>(when tested in the HSV1 Q&quot; assay)</td></tr></table>

# 510(k) Summary

# BD ProbeTecT™ Herpes Simplex Viruses (HSV1 & 2) Q Amplified DNA Assays

# Clinical Performance Characteristics

Clinician-collected external anogenital lesion swab specimens were collected from 564 compliant male and female subjects attending family planning, OB/GYN, and sexually transmitted disease clinics at nine geographically diverse clinical sites in North America. Subjects were classified as symptomatic if they presented with an external anogenital lesion that met the study inclusion/exclusion criteria and the physician suspected a herpes infection. Fiftysix subjects were excluded from the data analysis due to age requirement violations, antiviral use in the last 21 days, opting to withdraw from the study after initially consenting, transport errors, informed consent issues, failing to meet the inclusion/exclusion criteria, collection errors, shipping errors, or labeling errors. Therefore, the final data analysis included 508 compliant subjects.

For each of the 508 compliant subjects, two swab specimens were collected from the external anogenital lesion. The first specimen collected was always the Universal Viral Transport specimen followed by the BD ProbeTec $\mathsf { Q } ^ { x }$ Collection Kit for Endocervical or Lesion Specimens $( \mathbf { Q } ^ { \mathbf { x } }$ Swab Diluent specimen). The UVT was aliquotted into a $\mathbf { Q } ^ { x }$ Swab Diluent Tube (UVT in ${ \sf { Q } } ^ { \tt { x } }$ EY Swab Diluent), and a cryovial (vial suitable for $- 7 0 \theta C$ storage), and the remaining UVT was sent to one of two laboratories for viral culture and typing. The ${ \sf Q } ^ { \tt x }$ Swab Diluent specimen and the UVT in ${ { \bf { Q } } ^ { \tt { x } } }$ Swab Diluent specimen were transported to one of the three BD Viper testing laboratories where they were tested using the BD ProbeTec HSV1 and HSV2 $\boldsymbol { \mathrm { Q } } ^ { \boldsymbol { \mathsf { x } } }$ Assays on the BD Viper System. The cryovial containing the UVT aliquot was sent to a laboratory for PCR testing.

All sensitivity and specificity calculations were based on the total number of BD ProbeTec HSV1 and HSV2 $\mathsf { Q } ^ { \tt x }$ Assays results for ${ \bf { Q } } ^ { \tt { r } }$ Swab Diluent and UVT in ${ \sf Q } ^ { \tt x }$ Swab Diluent specimens, as compared to a commercially available viral culture and typing procedure as the reference method. A PCR method was also used for analysis of discrepant results from the ProbeTec HSV $\mathsf { Q } ^ { \boldsymbol { x } }$ Amplified DNA Assays and the reference culture and typing method.

# BD ProbeTec™ Herpes Simplex Viruses (HSV1 & 2) Q Amplified DNA Assays

Table 3: HSV1 ${ \bf { 0 } } ^ { x }$ Assay Performance Compared to Viral Culture (by specimen type)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>Performance Compared to Viral Culture</td></tr><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>n{</td><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>95% C.I.;</td><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1> 95% C.I..</td></tr><tr><td rowspan=1 colspan=1>UVT inQ&quot; SwabDiluent</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>96.8% (60/62)3</td><td rowspan=1 colspan=1>(88.8% - 99.6%)</td><td rowspan=1 colspan=1>97.6%(244/250) 4</td><td rowspan=1 colspan=1>(94.8%-99.1%)</td></tr><tr><td rowspan=1 colspan=1>Q&quot; SwabDiluent</td><td rowspan=1 colspan=1>3082</td><td rowspan=1 colspan=1>96.7% (59/61)3</td><td rowspan=1 colspan=1>(88.7% - 99.6%)</td><td rowspan=1 colspan=1>95.1%(235/247)5.</td><td rowspan=1 colspan=1>(91.7%-97.5%)</td></tr></table>

(501) minus the number of samples positive for HSV2 by the reference method (189).

$\mathsf { Q } ^ { \tt F }$ extraction error..   
HSV Q" Assays and the PCR assay identified the subjects as positive for HSV2.   
  
HSV1 ${ \sf Q } ^ { \tt x }$ Assay and the PCR assay.   
Assay. Seven of these specimens were also positive with the PCR assay.

Table 4: HSV2 O" Assay Performance Compared to Viral Culture (by specimen type)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>Performance Compared to Viral Culture</td></tr><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>95% C.l.</td><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>UVT inQ*SwabDiluent</td><td rowspan=1 colspan=1>501</td><td rowspan=1 colspan=1>98.4% (186/189)6</td><td rowspan=1 colspan=1>(95.4% -99.7%)</td><td rowspan=1 colspan=1>83.7%(261/312)7,.9</td><td rowspan=1 colspan=1>(79.1%-87.6%)</td></tr><tr><td rowspan=1 colspan=1>Q&quot; SwabDiluent</td><td rowspan=1 colspan=1>498</td><td rowspan=1 colspan=1>98.4% (186/189)6</td><td rowspan=1 colspan=1>(95.4% -99.7%)</td><td rowspan=1 colspan=1>80.6%(249/309).9</td><td rowspan=1 colspan=1>(75.7% -84.8%)</td></tr></table>

${ { \sf Q } ^ { \tt x } }$ assay. Both the HSV Q" Assays and the PCR assays identified all three subjects as positive for HSV1. f the 51 HSV2 UVT in  Swab Dilunt positive nd virl cultue negative wee postiv or HSV2 by PCR. i $\mathsf { Q } ^ { \tt r }$ particles.

# 510(k) Summary

# BD ProbeTec™ Herpes Simplex Viruses (HSV1 & 2) Q Amplified DNA Assays

Frequency distributions of the initial MaxRFU values for the HSV1 ${ \bf { \cal Q } } ^ { x }$ Assay with an assay cutoff of 125 MaxRFU for specimens in each media type are shown in Figures A and B.

![](images/79ddbde020cc7fa95c8ef78809da8aa46f7e8c00d2b95d35bf9e05fa73123979.jpg)  
Figure A: Frequency Distribution of MaxRFU for the HSV1 $\mathbf { Q } ^ { \boldsymbol { x } }$ Assay, UVT in $\mathbf { Q } ^ { \mathbf { x } }$ Swab Diluent

![](images/3a37e7d59c6a4b1740a1653a8b6291e1e8cecdc4ef58a158a447f18bfcffbd7c.jpg)  
Figure B: Frequency Distribution of MaxRFU for the HSV1 $\mathbf { Q } ^ { \star }$ Assay, $\mathbf { Q } ^ { \mathbf { x } }$ Swab Diluent

Frequency distributions of the initial MaxRFU values for the HSV2 $\mathbf { Q } ^ { x }$ Assay with an assay cutoff of 125 MaxRFU for specimens in each media type are shown in Figures C and D.

# BD ProbeTec™ Herpes Simplex Viruses (HSV1 & 2) Q Amplified DNA Assays

![](images/132b9e3c31d29b7e55d747898c28438d7bd53f6755d9e4a5369b79cfda1fec7d.jpg)  
Figure C: Frequency Distribution of MaxRFU for the HSV2 ${ \bf { Q } } ^ { \bf { { x } } }$ Assay, UVT in $\mathbf { Q } ^ { \mathbf { x } }$ Swab Diluent

![](images/fd321e13c6832957bf033ea56577d7779d629e1856891a66a50d7de203443eb7.jpg)  
Figure D: Frequency Distribution of MaxRFU for the HSV2 $\mathbf { Q } ^ { x }$ Assay, $\mathbf { Q } ^ { \mathbf { x } }$ Swab Diluent

# Reproducibility

Reproducibility of the BD Viper System using the BD ProbeTec HSV1 and HSV2 ${ { \bf { \cal Q } } ^ { \bf { { x } } } }$ Assays was evaluated at three test sites (two external and one internal) on one BD Viper System per site. Two panels of simulated specimens were tested that were comprised of HSV1 (strain VR-539) and/or HSV2 (strain VR-734) viral particles seeded into either $\mathbf { Q } ^ { x }$ Swab Diluent containing a swab (simulated $\mathsf { Q } ^ { x }$ Swab Diluent) or UVT in $\mathsf { Q } ^ { \boldsymbol { x } }$ Swab Diluent (simulated UVT in ${ \sf Q } ^ { \tt x }$ Swab Diluent specimen type). Viral particles were spiked into the simulated samples at 2-fold or 5-fold LOD. Uninoculated ${ \sf Q } ^ { x }$ Swab Diluent or UVT in $\mathsf { Q } ^ { \boldsymbol { x } }$ Swab Diluent was used for the negative samples. Six replicates of each panel member were tested every day for five days on each BD Viper System. A summary of the reproducibility data for the HSV1 and HSV2 ${ \sf Q } ^ { \tt x }$ Assays is presented in Tables 7 and 8.

Table 7: Summary of Reproducibility Data on the BD Viper System for the HSV1 Qx Assay.   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Site #1</td><td rowspan=1 colspan=4>Site #2      *</td><td rowspan=1 colspan=4>Site #3</td><td rowspan=1 colspan=2>.P</td></tr><tr><td rowspan=1 colspan=1>:SimulatedSpecimenPType</td><td rowspan=1 colspan=1>TargetsHSVI/HSV2(xLOD)**</td><td rowspan=1 colspan=1>AgreementwithExpectedResults</td><td rowspan=1 colspan=1>MaxRFUMean</td><td rowspan=1 colspan=1>MaxRFUStdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>:AgreementwithExpectedResults</td><td rowspan=1 colspan=1>MaxRFUMean</td><td rowspan=1 colspan=1>MaIRFUStdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>-↓2AgreementwithExpectedResults</td><td rowspan=1 colspan=1>MaxRFUMean</td><td rowspan=1 colspan=1>Ma1RFUStdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>TotalAgreementwithExpectedResults(%)</td><td rowspan=1 colspan=1>95%ConfidenceInterval</td></tr><tr><td rowspan=5 colspan=1>UVT inQ SwabDDiluent&quot;</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=1 colspan=1>2x/0</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>1432.6</td><td rowspan=1 colspan=1>447.6</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1375.4</td><td rowspan=1 colspan=1>326.2</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1474.5</td><td rowspan=1 colspan=1>307.9</td><td rowspan=1 colspan=1>20.9</td><td rowspan=1 colspan=1>89/90(98.9%)</td><td rowspan=1 colspan=1>94%-100%</td></tr><tr><td rowspan=1 colspan=1>0/2x i.</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>10.9</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>27.6</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=1 colspan=1>2x/5x</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>1123.1</td><td rowspan=1 colspan=1>622.9</td><td rowspan=1 colspan=1>55.5</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1144.9</td><td rowspan=1 colspan=1>397.7</td><td rowspan=1 colspan=1>34.7</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1441.4</td><td rowspan=1 colspan=1>205.8</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>89/90(98.9%)</td><td rowspan=1 colspan=1>94%-100%</td></tr><tr><td rowspan=1 colspan=1>5x/2x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1586.2</td><td rowspan=1 colspan=1>346.8</td><td rowspan=1 colspan=1>21.9</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1531.5</td><td rowspan=1 colspan=1>165.4</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1619.7</td><td rowspan=1 colspan=1>175.7</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=5 colspan=1>Q&#x27; SwabDiluent</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>24.9</td><td rowspan=1 colspan=1>39.0</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>15.5</td><td rowspan=1 colspan=1>84.7</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>· 3.8</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>88/90(97.8%)</td><td rowspan=1 colspan=1>92.2%99.7%</td></tr><tr><td rowspan=1 colspan=1>2x/0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1477.2</td><td rowspan=1 colspan=1>392.3</td><td rowspan=1 colspan=1>26.6</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>999.2</td><td rowspan=1 colspan=1>482.9</td><td rowspan=1 colspan=1>48.3</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1276.7</td><td rowspan=1 colspan=1>396.0</td><td rowspan=1 colspan=1>31.0</td><td rowspan=1 colspan=1>88/90(97.8%)</td><td rowspan=1 colspan=1>92.2%99.7%</td></tr><tr><td rowspan=1 colspan=1>0/2x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96% -100%</td></tr><tr><td rowspan=1 colspan=1>2x/5x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1551.0</td><td rowspan=1 colspan=1>369.1</td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1395.1</td><td rowspan=1 colspan=1>144.3</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1320.5</td><td rowspan=1 colspan=1>349.9</td><td rowspan=1 colspan=1>26.5</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96% -100%</td></tr><tr><td rowspan=1 colspan=1>5x/2x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1751.5</td><td rowspan=1 colspan=1>174.0</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1441.8</td><td rowspan=1 colspan=1>214.8</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1535.1</td><td rowspan=1 colspan=1>244.1</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr></table>

\* HSV1 and HSV2 were spiked at either 2-fold (2x) or 5-fold $( 5 \mathbf { x } )$ the LOD.

# 510(k) Summary

# BD ProbeTec™ Herpes Simplex Viruses (HSV1 & 2) Q Amplified DNA Assays

Table 8: Summary of Reproducibility Data on the BD Viper System for the HSV2 ${ \bf { Q } } ^ { \bf { r } }$ Assay.   

<table><tr><td rowspan=1 colspan=2>EMPY</td><td rowspan=1 colspan=4>Site #1</td><td rowspan=1 colspan=4>. Site #2</td><td rowspan=1 colspan=4>Site #3</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>SimplatedSpecimenType</td><td rowspan=1 colspan=1>TargetsHSV1/HSV2(xXLD)*</td><td rowspan=1 colspan=1>AgreementwithExpectedResults</td><td rowspan=1 colspan=1>MaxRFUMean</td><td rowspan=1 colspan=1>MaxRFUStdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>AgreementwithExpectedResults</td><td rowspan=1 colspan=1>1MaxRFUMean</td><td rowspan=1 colspan=1>*MaxRFUStdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>AgreementwithExpectedResults</td><td rowspan=1 colspan=1>.MaxRFUMean</td><td rowspan=1 colspan=1>MaxRFUStdDev</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>TotalAgreementwithExpectedResults(%)</td><td rowspan=1 colspan=1>95%ConfidenceIaterval</td></tr><tr><td rowspan=5 colspan=1>UVT inQ&#x27; SwbDDiluent</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>29/29***</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>16.4</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>89/89(100%)</td><td rowspan=1 colspan=1>95.9%-100%</td></tr><tr><td rowspan=1 colspan=1>2x/0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>14.4</td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=1 colspan=1>0/2x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1768.6</td><td rowspan=1 colspan=1>390.0</td><td rowspan=1 colspan=1>22.0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1806.1</td><td rowspan=1 colspan=1>263.6</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1910.6</td><td rowspan=1 colspan=1>236.5</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=1 colspan=1>2x/5x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1946.5</td><td rowspan=1 colspan=1>246.8</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1800.1</td><td rowspan=1 colspan=1>267.6</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1965.1</td><td rowspan=1 colspan=1>171.7</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=1 colspan=1>5x\2x</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1866.1</td><td rowspan=1 colspan=1>319.9</td><td rowspan=1 colspan=1>17.1</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1823.8</td><td rowspan=1 colspan=1>250.8</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1861.2</td><td rowspan=1 colspan=1>224.8</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=5 colspan=1>:Q&quot; SwabDiluent</td><td rowspan=1 colspan=1>0/0:</td><td rowspan=1 colspan=1>29/29***</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>19.1</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>89/89(100%)</td><td rowspan=1 colspan=1>95.9%-100%</td></tr><tr><td rowspan=1 colspan=1>2x/0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>96%-100%</td></tr><tr><td rowspan=1 colspan=1>0/2x</td><td rowspan=1 colspan=1>29/29***</td><td rowspan=1 colspan=1>2007.1</td><td rowspan=1 colspan=1>219.4</td><td rowspan=1 colspan=1>10.9</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1679.5</td><td rowspan=1 colspan=1>331.1</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1757.3</td><td rowspan=1 colspan=1>289.2</td><td rowspan=1 colspan=1>16.5</td><td rowspan=1 colspan=1>89/89(100%)</td><td rowspan=1 colspan=1>95.9%-100%</td></tr><tr><td rowspan=1 colspan=1>2x/5x</td><td rowspan=1 colspan=1>29/29***</td><td rowspan=1 colspan=1>2028.3</td><td rowspan=1 colspan=1>230.6</td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1787.5</td><td rowspan=1 colspan=1>327.9</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1882.7</td><td rowspan=1 colspan=1>342.1</td><td rowspan=1 colspan=1>18.2</td><td rowspan=1 colspan=1>89/89(100%)</td><td rowspan=1 colspan=1>95.9%-100%</td></tr><tr><td rowspan=1 colspan=1>5x/2</td><td rowspan=1 colspan=1>29/29***</td><td rowspan=1 colspan=1>1960.7</td><td rowspan=1 colspan=1>254.7</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1756.2</td><td rowspan=1 colspan=1>286.7</td><td rowspan=1 colspan=1>16.3</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>1762.7</td><td rowspan=1 colspan=1>350.3</td><td rowspan=1 colspan=1>19.9</td><td rowspan=1 colspan=1>89/89(10%)</td><td rowspan=1 colspan=1>95.9%-100%</td></tr></table>

\*\* HSV1 and HSV2 were spiked at either 2-fold $( 2 \mathbf { x } )$ or 5-fold $( 5 \mathbf { x } )$ the LOD.

# Conclusions:

The analytical and clinical study results for the BD ProbeTec Herpes Simplex Viruses (HSV) $\boldsymbol { \mathrm { Q } } ^ { \tt x }$ Amplified DNA Assays support the determination of substantial equivalence in accordance with the intended use as stated in the product labeling.

BD Diagnostic Systems c/o Thalia Charles Regulatory Affairs Specialist 7 Loveton Circle Sparks, MD 21152

# MAR 1 8 2011

Re: K103798 Trade/Device Name: BD ProbeTec Herpes Simplex Viruses (HSV 1 & 2 $\boldsymbol { \mathrm { Q } } ^ { x }$ Amplifie DNA Assays Regulation Number: 21 CFR $\ S 8 6 6 . 3 3 0 5$ Regulation Name: Herpes Simplex Virus Nucleic Acid Amplification Assay Regulatory Class: Class II Product Code: 0QO Dated: December 22, 2010 Received: December 27, 2010

Dear Ms. Charles:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, tacot

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): K103798

Device Name: BD ProbeTecTM Herpes Simplex Viruses (HSV 1 & 2) $\mathbf { Q } ^ { \star }$ Amplified DNA Assays

Indications For Use:

The BD ProbeTecTM Herpes Simplex Viruses (HSV 1 & 2) $\boldsymbol { \mathbf { Q } } ^ { x }$ Amplified DNA Assays, when tested with the BD Viper™M System in Extracted Mode, use Strand Displacement Amplification technology for the direct, qualitative detection and differentiation of Herpes Simplex virus type 1 (HSV1) and Herpes Simplex virus type 2 (HSV2) DNA in clinician-collecte external anogenital lesin speciens.The assays are indiated for use with symptomatic individuals to aid in the diagnosis of anogenital HSV1 and HSV2 infections.

Warning: The BD ProbeTecTM Herpes Simplex Viruses (HSV 1 & 2) $\mathbf { Q } ^ { x }$ Amplified DNA Assays (HSV Q° As) are ot FDA cle r use wih ceral flui S).The assys are ot in o be us for prenatal screening or for individuals under the age of 17 years.

Prescription Use V AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

![](images/01a5a06f55f82f1c9af33a4c9e003cef9a402885c8e6da8819f6a58bfc57e796.jpg)  
Page l of 1

Office of In Vitro Diagnostic Device Evaluation and Safety